Laniquidar (R101933) 是一种非竞争性的第三代P-glycoprotein (P-gp)抑制剂，IC50值为 0.51 μM。Laniquidar 可用于多药耐药转运体的调控。Laniquidar 也可用于研究急性髓细胞白血病 (AML) 和骨髓增生异常综合征 (MDS)。 Laniquidar口服生物利用度有限。

Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC 50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters [1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [2]. Laniquidar has limited oral bioavailability [3].

197509-46-9

C37H36N4O3

584.71

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years